Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefotetan disodium
Drug ID BADD_D00392
Description A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.
Indications and Usage For prophylaxis and treatment of bacterial infections.
Marketing Status approved
ATC Code J01DC05
DrugBank ID DB01330
KEGG ID D02228
MeSH ID D015313
PubChem ID 53024
TTD Drug ID D0AP9T
NDC Product Code 63323-386; 63323-385; 52946-0834
UNII 0GXP746VXB
Synonyms Cefotetan | Apatef | Cefotetan Disodium | Disodium, Cefotetan | Cefotetan Disodium Salt | Disodium Salt, Cefotetan | Salt, Cefotetan Disodium | ICI-156834 | ICI 156834 | ICI156834 | YM-09330 | YM 09330 | YM09330 | Apacef | Ceftotan | Cefotan
Chemical Information
Molecular Formula C17H15N7Na2O8S4
CAS Registry Number 74356-00-6
SMILES CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)[O-])S4)OC)SC2)C(=O)[O- ].[Na+].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neutropenia01.02.03.004---
Pancytopenia01.03.03.003---
Phlebitis12.02.01.002; 24.12.03.004--
Prothrombin level increased13.01.02.011---
Prothrombin time prolonged13.01.02.012---
Pruritus23.03.12.001--
Pseudomembranous colitis07.19.01.003; 11.02.02.002---
Pyrexia08.05.02.003--
Rash23.03.13.001---
Seizure17.12.03.001--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Superinfection11.01.08.009---
Thrombocytopenia01.08.01.002---
Thrombocytosis01.08.02.001---
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Urticaria10.01.06.001; 23.04.02.001--
Vaginal infection11.01.10.002; 21.14.02.002--
Vomiting07.01.07.003--
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Haemorrhage24.07.01.002---
Blood alkaline phosphatase increased13.04.02.004--
Renal impairment20.01.03.010---
Vulvovaginal mycotic infection11.03.05.004; 21.14.02.004---
Vulvovaginal inflammation21.14.02.014---
The 2th Page    First    Pre   2    Total 2 Pages